



1145 Corporate Lake Drive, Suite 100  
St. Louis, Missouri 63132, USA  
Tel 314.993.0003  
Toll Free 800.878.4267  
Fax 314.993.0075

For more information: David Murphy  
Senior Director of Marketing and Communications  
CMS  
Tel: (314) 812-4320  
[dmurphy@cmsrtp.com](mailto:dmurphy@cmsrtp.com)  
9991-952-23A

### **CMS, Inc. Collaborates with Still River Systems for Proton Beam Therapy *XiO Treatment Planning Solution to Support New Proton Delivery System***

**St Louis, MO (July 20, 2007)** – CMS, Inc., the worldwide market leader in radiation treatment planning and workflow management, announced the signing of a collaboration agreement to provide treatment planning support for the new single-room proton beam radiotherapy system being developed by Still River Systems.

The partnership leverages CMS's existing clinical capabilities and market leadership position in proton treatment planning solutions with Still River Systems' new proton delivery technology. Pursuant to the agreement, CMS and Still River Systems will work together to ensure that CMS's XiO treatment planning system interfaces with and supports the specific planning requirements of Still River Systems' Clinatron 250™ proton treatment system currently in development.

CMS' XiO is a comprehensive treatment planning system that combines the latest tools and the most robust dose calculation algorithms, allowing users to generate treatment plans quickly and accurately to optimize the delivery of radiation therapy. XiO's integrated planning capabilities support a range of treatment modalities, including 3-D, MLC-based IMRT (both sliding window and step-and-shoot), solid compensator-based IMRT, brachytherapy, and proton therapy. XiO leverages the speed and performance capabilities of the Linux operating system and the processing power of dual Intel processors to deliver superior 3-D image rendering, real-time image manipulation, and rapid calculation times.

XiO supports proton as well as conventional photon and electron planning. Developed over a decade ago in collaboration with leading researchers and clinicians at the Massachusetts General Hospital, XiO's proton planning capabilities are utilized at leading proton treatment sites and research institutions around the world, including MGH and the Midwest Proton Radiotherapy Institute in the United States. Currently, CMS has more proton facilities using its planning solutions than any other commercial vendor, and its systems are used in conjunction with IBA, Varian/Accel and Mitsubishi delivery systems.

"We are delighted to partner with Still River Systems to provide proton treatment planning solutions in conjunction with their new delivery technology," said Andrew C. Cowen, President and CEO of CMS. "Proton treatment allows for more precise dose targeting relative to conventional radiation therapy, thereby permitting increased dose to treatment volumes with less damage to healthy surrounding tissues, and has led to increased long term disease-free survival rates for many types of tumors. Proton therapy has the potential to transform cancer care, and Still River Systems' cost-effective single-room solution has the potential to make this important new technology accessible to more cancer patients around the world."

CMS is a worldwide leader in the development and support of radiation treatment planning and workflow management solutions. With treatment planning systems installed in more than 1,500 sites worldwide, CMS is a global resource to radiation oncology community. A privately held corporation, CMS employs over 285 professionals in its headquarters located in St. Louis, MO and regional offices in Tampa, Florida; Freiburg, Germany; Tokyo, Japan; Sydney, Australia; and Shanghai, China.

**Forward-Looking Statements**

*Statements contained in this release, which are not historical facts, may be considered "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations and the current economic environment.*

*We caution the reader that such forward-looking statements are not guarantees of future performance. Unknown risk, uncertainties as well as other uncontrollable or unknown factors could cause actual results to materially differ from the results, performance or expectations expressed or implied by such forward-looking statements.*